Lido Advisors LLC lifted its position in shares of Tabula Rasa HealthCare Inc (NASDAQ:TRHC) by 21.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,000 shares of the company’s stock after acquiring an additional 4,600 shares during the quarter. Lido Advisors LLC’s holdings in Tabula Rasa HealthCare were worth $2,110,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of the company. Mount Yale Investment Advisors LLC acquired a new position in shares of Tabula Rasa HealthCare during the 2nd quarter worth about $111,000. Meadow Creek Investment Management LLC acquired a new position in shares of Tabula Rasa HealthCare during the 2nd quarter worth about $115,000. Envestnet Asset Management Inc. acquired a new position in shares of Tabula Rasa HealthCare during the 2nd quarter worth about $130,000. Pinebridge Investments L.P. acquired a new position in shares of Tabula Rasa HealthCare during the 2nd quarter worth about $181,000. Finally, Piedmont Investment Advisors LLC acquired a new position in shares of Tabula Rasa HealthCare during the 2nd quarter worth about $206,000. 74.88% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts recently weighed in on the stock. Citigroup upped their price target on shares of Tabula Rasa HealthCare from $57.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Piper Jaffray Companies upped their price target on shares of Tabula Rasa HealthCare to $71.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 8th. Stifel Nicolaus assumed coverage on shares of Tabula Rasa HealthCare in a research report on Tuesday, September 11th. They set a “hold” rating and a $95.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Tabula Rasa HealthCare in a research report on Thursday, September 6th. They set an “overweight” rating and a $99.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the stock. Tabula Rasa HealthCare presently has an average rating of “Buy” and a consensus target price of $82.50.
TRHC stock opened at $72.38 on Thursday. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -1,809.50, a price-to-earnings-growth ratio of 6.84 and a beta of 2.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.49 and a quick ratio of 0.46. Tabula Rasa HealthCare Inc has a 12 month low of $27.25 and a 12 month high of $91.16.
Tabula Rasa HealthCare (NASDAQ:TRHC) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.07. The company had revenue of $54.42 million during the quarter, compared to the consensus estimate of $52.87 million. Tabula Rasa HealthCare had a negative net margin of 13.49% and a positive return on equity of 7.63%. Tabula Rasa HealthCare’s quarterly revenue was up 66.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.08 EPS. On average, sell-side analysts expect that Tabula Rasa HealthCare Inc will post 0.42 earnings per share for the current year.
In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $85.98, for a total value of $687,840.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gordon Tunstall sold 10,000 shares of the stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $70.52, for a total transaction of $705,200.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,000 shares of company stock valued at $4,343,760. 14.00% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This news story was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://transcriptdaily.com/2018/12/06/tabula-rasa-healthcare-inc-trhc-stake-raised-by-lido-advisors-llc.html.
Tabula Rasa HealthCare Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Want to see what other hedge funds are holding TRHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tabula Rasa HealthCare Inc (NASDAQ:TRHC).
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.